Yissum, the tech transfer office (TTO) of Hebrew University, appointed Yaron Daniely (pictured), as its chief executive this month.
Daniely, who stepped down as CEO at cognitive therapeutics developer Alcobra on May 31, but then became the company’s chairman, had spent seven years in that post.
His resume includes stints at other Israel-based pharmaceuticals developers, including as director at Bioblast from 2012 to 2014, and as chief executive of Nanocyte Medical between 2007 and 2010.
Yissum has secured more than 9,300 patents for 2,600 inventions since launching in 1964. The TTO has spun out 110 companies and currently generates $2bn in revenue each year from commercialised Hebrew University technologies.
Daniely said: “It has been an honour to lead Alcobra over the past seven years. I am proud of what we have accomplished, and believe the company has made significant progress over the past few months to advance potential value creation.”
Howard Rosen, outgoing chairman at Alcobra, added: “Dr Daniely has been a driven and passionate leader for the company and we thank him for years as service as CEO and wish him all the best as CEO of Yissum.”
– Image courtesy of LinkedIn
